Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Rocket begins phase I study of RP-L401 in infantile malignant osteopetrosis

Feb. 19, 2021

AAV-mediated gene therapy FLT-201 shows robust potency for treating Gaucher disease

Feb. 19, 2021

Immunotherapy targeting AT1R ameliorates experimental insulin resistance

Feb. 19, 2021

ABO-102 demonstrates evidence of clinical benefit in patients with MPS IIIA

Feb. 18, 2021

Highly phosphorylated GCase M-011 exhibits improved potential in Gaucher disease

Feb. 18, 2021

AT-GTX-501 slows motor and language function decline in vLINCL6

Feb. 17, 2021

Updated phase I/II data for ABO-101 gene therapy in patients with MPS IIIB

Feb. 17, 2021

Valbiotis gains French clearance to begin phase II study of TOTUM-070 to reduce LDL-cholesterol

Feb. 16, 2021

Orchard Therapeutics reports data from trial of OTL-201 in MPS type III A

Feb. 16, 2021

SIG-018 ameliorates symptoms of MPS II in preclinical models

Feb. 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...